Dr. Andrew Dahl MD

GLG News^SM Analyses by Andrew Dahl

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Medicare is not a free lunch

June 1, 2011

Analysis of:Democrats Say Win in New York U.S. House Race Sends Message on Medicare | www.bloomberg.com

The New York 26th district congressional election results last week are being portrayed as a victory for those opposing the Ryan plan to provide varying (based on income)  amount of dollars to Medicare recipients for them to purchase health insurance under a competitive system within the insurance industry.  This plan would be voluntary for the next ten years, so that anyone 55 or older at present could remain in traditional Medicare for the rest of their lives..

VEGF TRAP shows equal efficacy to Lucentis with longer duration of effect in DME

February 19, 2010

Analysis of:VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema | www.pipelinereview.com

Interim six month data from the DAVINCI clinical trial showed that monthly injections of intravitreal VEGF TRAP in patients with diabetic macular edema produced approximately a 10 letter increase in visual acuity. Patients dosed with 3 initial monthly injections followed as needed injections achieved a similar result. In this latter group, average number of injections in the second three months was 1.4.Injections were well tolerated without serious side effects. The study is continuing

Lumigan X EU Committee Recomendation

October 27, 2009

Analysis of:EU committee backs marketing approval of Lumigan | www.pharmabiz.com

The Committee for Medicinal Products for Human Use (CHMP) of the European Union has recommended granting a Marketing Authorization for a new version of Allergan's Lumigan (bimatoprost ophthalmic solution). This new version will be marketed as Lumigan-X after approval. Lumigan X offers Allergan a new formulation to compete against generic versions of its glaucoma drug Lumigan after patent protection for Lumigan expires shortly.There will be very limited demand for Lumigan-X.

U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol Combo

November 8, 2007

Analysis of:Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com

The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent rights on the combination whose two components individually have multiple generic competitors.                          

Interesting Approach to the Lucrative Dry Eye Market

October 16, 2007

Analysis of:Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 | www.pipelinereview.com

Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small clinical trial produced promising results, the FDA will require both subjective (patients feeling better) and objective (decreased conjunctival and corneal staining) statistical advantage over placebo in two phase III trials prior to approval of the eye drop drug.

View All GLG News ^SM Analyses by Andrew Dahl